Why retaliatory tariffs could cost lives and what we should do instead

For Canada’s life sciences sector, the stakes are even higher in the trade war with the U.S.—both livelihoods and lives are at risk.

Prime Minister Mark Carney must carefully consider the unintended consequences of targeting pharmaceuticals and medical devices in retaliatory tariffs, which could disrupt supply chains, lead to drug shortages, and deter clinical trial investments, writes Jason Field.The Hill Times photograph by Andrew Meade

Opinion

BY JASON FIELD

April 2, 2025

The ongoing trade war between Canada and the United States has dominated headlines, and has become a central topic of discussion at dinner tables across the country. It's even emerged as a key issue in the upcoming federal election. Many Canadian industries are bracing for t...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy